The randomized phase 3 CheckMate 238 trial evaluated the safety and efficacy of nivolumab vs ipilimumab in the resected stage III/IV melanoma setting.
The KEYNOTE-045 trial randomly assigned 542 patients with UC who progressed after 2 or fewer prior therapies to receive pembrolizumab or investigator's choice of paclitaxel, docetaxel, or vinflunine.
Researchers randomly assigned 140 patients with metastatic pancreatic cancer to receive eryaspase with standard of care FOLFOX or chemotherapy alone.
Patients had similar HRQOL scores by all measures at baseline, but experienced significant changes in scores for the HRQOL domains of Body Image, Diarrhea, Nutrition, Pain, and Role Function.
Patients who received osimertinib had a PFS of 18.9 months compared with 10.2 months among those who received SoC treatments (P < .0001).
The results of the study demonstrate that increased TIL levels may be associated with a greater response to pembrolizumab monotherapy in patients with mTNBC, especially in the first-line setting.
Researchers compared the efficacy of abemaciclib plus anastrozole or letrozole vs placebo plus anastrozole or letrozole among patients not previously treated with a systemic therapy.
Researchers randomly assigned 713 patients with NSCLC who did not progress after 2 or more cycles of platinum-based concurrent chemoradiation therapy to receive durvalumab 10 mg/kg consolidation therapy or placebo for up to 12 months.
Although these data did not demonstrate improved survival with the inclusion of a CT scan at routine follow-up visits, the authors noted that a longer follow-up time is necessary to identify any long-term OS benefits.
Alterations conferring resistance to targeted agents were identified among 18% of samples from NSCLC, breast, colorectal, and prostate cancers, melanoma, and gastrointestinal stromal tumors.
Long-term hormone monotherapy has been the standard of care for patients with PCa for more than 60 years. The purpose of this study was to compare the efficacy of 2 new treatment standards using a patient subset of the STAMPEDE trial.
The relative effects of FLOT were demonstrable in all subgroups, and was pronounced numerically in patients with Barrett tumors, small tumors T1/2, nodal negative tumors, and Siewert type 1 esophageal tumors.
The phase 3 OAK trial demonstrated that previously treated patients with advanced NSCLC experienced prolonged OS with atezolizumab compared to docetaxel regardless of PD-L1 status.
Researchers find BRCA2 mutations are associated with worse outcomes among men with mCRPC.
Similar Efficacy, Less Toxicity with Neoadjuvant Letrozole/Palbociclib Versus Chemo in Breast CancerSeptember 08, 2017
Although there was less toxicity, neoadjuvant letrozole plus palbociclib had similar response and BCS rates when compared with chemotherapy.
Patients with untreated FL were randomly assigned to receive cyclophosphamide, vincristine, and prednisone (CVP) plus rituximab (R) or GP2013 for 8 cycles followed by 2 years of monotherapy maintenance in patients who responded to treatment.
Although guidelines advocate follow-ups consisting of clinic visits and CT-scans, there is a lack of robust data supporting these recommendations.
This trial sought to determine if the letrozole and taselisib combination was effective in early-stage breast cancer.
Cabozantinib and nivolumab (CaboNivo) with or without ipilimumab (Ipi) demonstrated manageable safety profiles and durable clinical activity.
Though a longer overall survival was observed in patients who received pertuzumab plus trastuzumab and chemotherapy, it was not statistically significant.
The non-inferiority of the sorafenib (So) and pazopanib (Pa) sequence was not demonstrated compared to pazopanib-sorafenib in patients with metastatic renal cell carcinoma (mRCC).
Immune checkpoint inhibition may improve the efficacy of vaccine-induced T cells in incurable HPV genotype 16-positive cancer.
Adoptive cellular immunotherapy has not been widely used for cancer treatment.
Binimetinib a BRAF inhibitor, improved objective response rate (ORR) and progression-free survival (PFS) among patients with BRAF-mutant melanoma.
Surgical resection of soft tissue or visceral sarcoma conducted at an expert center resulted in substantially better outcomes compared with nonexpert centers.
First-line nivolumab plus radiotherapy (RT) with or without temozolomide was tolerated by patients with glioblastoma.
First-line treatment failed to improve progression-free survival among women of European descent with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy